[Form 4] Bunge Global SA Insider Trading Activity

Rhea-AI Filing Summary

On July 2, 2025, Bunge Global SA (ticker: BG) filed a Form 4 detailing an insider equity award to board member Anne Jensen. The filing, submitted on July 7, 2025, shows that Ms. Jensen received 2,164 Restricted Stock Units (RSUs) at no cost. Each RSU converts into one share of BG common stock and is scheduled to vest in full on May 15, 2026.

Following this grant, Ms. Jensen directly owns 2,164 shares of BG; no other non-derivative or derivative transactions were reported. The document was signed by Drew Yaeger as attorney-in-fact. The award represents routine director compensation aimed at strengthening alignment between the board and shareholders and has no immediate cash impact on the company. Given the small number of shares relative to BG’s total shares outstanding, the transaction is considered immaterial from a dilution or valuation standpoint.

Positive

• Equity alignment: Director compensation delivered entirely in RSUs, fostering shareholder alignment until May 15, 2026.

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine Form 4 shows director granted 2,164 RSUs; minimal dilution, standard alignment move, neutral impact on BG valuation.

The filing records a standard equity grant to director Anne Jensen. At 2,164 shares, the award is negligible versus Bunge’s multi-hundred-million share base and therefore non-material to financials or float. Absence of sales indicates no insider bearishness; instead, it simply adds another vesting tranche that will convert in May 2026. Because no derivatives or option exercises were disclosed, there is no leverage or hedging signal. Investors can view the grant as routine governance practice rather than a market-moving event.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jensen Anne

(Last) (First) (Middle)

C/O BUNGE GLOBAL SA

1391 TIMBERLAKE MANOR PARKWAY

(Street)

CHESTERFIELD MO 63017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bunge Global SA [ BG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/02/2025		A		2,164(1)	A	$0	2,164	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of Restricted Stock Units ("RSUs"). One RSU is convertible into one share of Bunge Global SA common stock. RSUs are expected to vest in full on May 15, 2026.

Remarks:

	/s/ Drew Yaeger, Attorney-in-Fact	07/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What securities did Anne Jensen acquire in the BG Form 4 filing?

She was granted 2,164 Restricted Stock Units, each convertible into one BG common share.

When will the RSUs granted to BG director Anne Jensen vest?

All RSUs are expected to vest on May 15, 2026.

How many BG shares does Anne Jensen own after the reported transaction?

She beneficially owns 2,164 shares of BG common stock, held directly.

Was any cash paid for the RSUs disclosed in the Form 4?

No. The RSUs were granted at $0 cost to the director.

Did the filing list any derivative security transactions?

No derivative securities were reported in Table II of the Form 4.